Gujarat Magazine

Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

 Breaking News
  • No posts were found

Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

July 04
17:45 2024
Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

  • July 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma. The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
  • July 2024:- AbbVie- A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
  • DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
  • The leading Advanced Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
  • Promising Advanced Hepatocellular Carcinoma Therapies such as Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma Emerging Drugs

Tivozanib : AVEO Oncology

FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Nofazinlimab: CStone Pharmaceuticals

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.

ECT 204: Eureka Therapeutics

ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Sintilimab: Eli Lilly and Company/Innovent

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Advanced Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
  • Advanced Hepatocellular Carcinoma Therapies- Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.
  • Advanced Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Hepatocellular Carcinoma Pipeline on our website @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Nofazinlimab: CStone Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase I/II)
  14. Tivozanib : AVEO Oncology
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Hepatocellular Carcinoma Key Companies
  21. Advanced Hepatocellular Carcinoma Key Products
  22. Advanced Hepatocellular Carcinoma – Unmet Needs
  23. Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
  24. Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
  25. Advanced Hepatocellular Carcinoma Analyst Views
  26. Advanced Hepatocellular Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/